{"success":true,"data":{"pressRelease":{"id":"165711","rtpr_id":"nGNX5sxVZ4-20261009","ticker":"MGRX","exchange":"NASDAQ","all_tickers":["MGRX"],"title":"Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close","author":"Globe Newswire","published_at":"2026-10-09T20:01:00.107Z","article_body":"Transaction follows a $2.5 million strategic investment commitment at MangoRx\nIP Holdings to support intellectual property commercialization\n\nDALLAS, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:\nMGRX) (“Mangoceuticals” or the “Company”), a company focused on\ndeveloping, marketing and selling health and wellness products through its\ntelemedicine platforms under the MangoRx and PeachesRx brands, today announced\nthe closing of a registered direct offering with a U.S.-based private\ninvestment firm, priced at a premium to the Company’s recent closing share\nprice. Management believes the transaction reflects investor interest in the\nCompany’s strategy and long-term opportunities.\n\nThe financing follows the Company’s October 1, 2026 announcement that its\nsubsidiary, MangoRx IP Holdings, LLC (“MangoRx IP”), entered into\nagreements for $2.5 million in aggregate strategic investment commitments in\nexchange for a 25% membership interest in its subsidiary. MangoRx IP has\nreceived $1.75 million of the committed capital, with the remaining $750,000\ndue by November 28, 2026, subject to the applicable agreement. This\nsubsidiary-level investment did not require the issuance of Mangoceuticals\ncommon stock or other parent-company securities. The proceeds are intended to\nadvance the commercialization of MangoRx IP’s intellectual property\nportfolio.\n\nTogether, the transactions provide capital at both the parent and subsidiary\nlevels through distinct structures. The registered direct offering provides\nadditional working capital to Mangoceuticals, while the subsidiary financing\nis intended to support intellectual property commercialization without\ndirectly diluting the publicly traded parent’s common stock through a\nsecurities issuance.\n\n“We believe the ability to attract a direct investment at a substantial\npremium to our recent trading price, shortly after securing strategic capital\ncommitments for MangoRx IP, is an encouraging development for\nMangoceuticals,” said Jacob D. Cohen, Chief Executive Officer. “These\ntransactions demonstrate our focus on pursuing financing structures suited to\ndifferent parts of our business. We intend to build on this momentum as we\nadvance commercialization initiatives and evaluate opportunities to create\nlong-term shareholder value.”\n\nTransaction Details\n\nThe approximately $500,000 registered direct offering closed on October 9,\n2026. The offering was priced at $0.75 per unit, with each unit consisting of\none share of common stock and one warrant. The unit purchase price represents\nan approximately 74% premium to the Company’s referenced recent closing\nshare price of $0.43. The transaction’s economic terms are described in the\nCompany's Current Report on Form 8-K filed with the SEC on October 9, 2026\n(the “Form 8-K”). Investors should review the Form 8-K and the offering\ndocuments filed as exhibits to the Form 8-K to understand the potential\ndilution that could result from exercises of the warrants.\n\nThe offering was made pursuant to an effective shelf registration statement on\nForm S-3 (No. 333-288039) previously filed with the U.S. Securities and\nExchange Commission (SEC) and declared effective by the SEC on June 24, 2025.\nA final prospectus supplement and accompanying prospectus describing the terms\nof the proposed offering were filed with the SEC and are available on the\nSEC’s website located at www.sec.gov. Electronic copies of the final\nprospectus supplement and the accompanying prospectus may be obtained by\ncontacting the Company at 17130 Dallas Parkway, Suite 240, Dallas, TX 75248,\nby email at investors@mangorx.com, or by telephone at +1 (214) 242-9619.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy nor shall there be any sale of these securities in any\nstate or jurisdiction in which such offer, solicitation or sale would be\nunlawful prior to registration or qualification under the securities laws of\nany such state or jurisdiction.\n\nAbout Mangoceuticals, Inc.\n\nMangoRx is focused on developing a variety of men’s health and wellness\nproducts and services via a secure telemedicine platform. The Company\ncurrently offers pharmaceutical-based products specifically related to the\ntreatments of erectile dysfunction, hair growth, hormone replacement\ntherapies, and weight management. Interested consumers can use MangoRx’s\ntelemedicine platform for a smooth experience. Prescription requests will be\nreviewed by a licensed medical provider and, if approved, fulfilled and\ndiscreetly shipped through MangoRx’s partner compounding pharmacy and right\nto the patient’s doorstep. To learn more about MangoRx’s mission and other\nproducts, please visit www.MangoRx.com.\n\nCautionary Note Regarding Forward-Looking Statements\n\nCertain statements made in this press release contain forward-looking\ninformation within the meaning of applicable securities laws, including within\nthe meaning of the Private Securities Litigation Reform Act of 1995\n(“forward-looking statements”). These forward-looking statements represent\nthe Company’s current expectations or beliefs concerning future events and\ncan generally be identified using statements that include words such as\n“estimate,” “expects,” “project,” “believe,” “anticipate,”\n“intend,” “plan,” “foresee,” “forecast,” “likely,”\n“will,” “target,” “up to” or similar words or phrases. These\nforward-looking statements include, but are not limited to, the timing and\nreceipt of the second tranche of subscription funds discussed above, the use\nof the proceeds of the investments and the outcome thereof; and the\ncommercialization and monetization of MangoRx IP’s intellectual property.\nAlthough we believe that our plans, intentions and expectations reflected in\nor suggested by the forward-looking statements we make in this release are\nreasonable, we provide no assurance that these plans, intentions or\nexpectations will be achieved. Consequently, you should not consider any such\nlist to be a complete set of all potential risks and uncertainties.\n\nMore information on potential factors that could affect the Company’s\nfinancial results is included from time to time in the “Cautionary Note\nRegarding Forward-Looking Statements,” “Risk Factors” and\n“Management’s Discussion and Analysis of Financial Condition and Results\nof Operations” sections of the Company’s filings with the SEC, including\nthe Company’s Annual Report on Form 10-K for the year ended December 31,\n2025 and our Quarterly Report on Form 10-Q for the quarter ended June 30,\n2026, and subsequent reports. These filings are available at www.sec.gov and\nat our website at https://www.mangoceuticals.com/sec-filings. All subsequent\nwritten and oral forward-looking statements attributable to the Company or any\nperson acting on behalf of the Company are expressly qualified in their\nentirety by the cautionary statements referenced above. Other unknown or\nunpredictable factors also could have material adverse effects on the\nCompany’s future results. The forward-looking statements included in this\npress release are made only as of the date hereof. The Company cannot\nguarantee future results, levels of activity, performance or achievements.\nAccordingly, you should not place undue reliance on these forward-looking\nstatements. Finally, the Company undertakes no obligation to update these\nstatements after the date of this release, except as required by law, and\ntakes no obligation to update or correct information prepared by third parties\nthat are not paid for by the Company. If we update one or more forward-looking\nstatements, no inference should be drawn that we will make additional updates\nwith respect to those or other forward-looking statements.\n\nFOR INVESTOR RELATIONS Email: investors@mangorx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/424c2f93-0321-4df2-98b6-6a7970d20bd4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5sxVZ4-20261009","title":"Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close","author":"Globe Newswire","ticker":"MGRX","created":"2026-10-09T20:01:00.107Z","tickers":["MGRX"],"exchange":"NASDAQ","article_body":"Transaction follows a $2.5 million strategic investment commitment at MangoRx\nIP Holdings to support intellectual property commercialization\n\nDALLAS, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:\nMGRX) (“Mangoceuticals” or the “Company”), a company focused on\ndeveloping, marketing and selling health and wellness products through its\ntelemedicine platforms under the MangoRx and PeachesRx brands, today announced\nthe closing of a registered direct offering with a U.S.-based private\ninvestment firm, priced at a premium to the Company’s recent closing share\nprice. Management believes the transaction reflects investor interest in the\nCompany’s strategy and long-term opportunities.\n\nThe financing follows the Company’s October 1, 2026 announcement that its\nsubsidiary, MangoRx IP Holdings, LLC (“MangoRx IP”), entered into\nagreements for $2.5 million in aggregate strategic investment commitments in\nexchange for a 25% membership interest in its subsidiary. MangoRx IP has\nreceived $1.75 million of the committed capital, with the remaining $750,000\ndue by November 28, 2026, subject to the applicable agreement. This\nsubsidiary-level investment did not require the issuance of Mangoceuticals\ncommon stock or other parent-company securities. The proceeds are intended to\nadvance the commercialization of MangoRx IP’s intellectual property\nportfolio.\n\nTogether, the transactions provide capital at both the parent and subsidiary\nlevels through distinct structures. The registered direct offering provides\nadditional working capital to Mangoceuticals, while the subsidiary financing\nis intended to support intellectual property commercialization without\ndirectly diluting the publicly traded parent’s common stock through a\nsecurities issuance.\n\n“We believe the ability to attract a direct investment at a substantial\npremium to our recent trading price, shortly after securing strategic capital\ncommitments for MangoRx IP, is an encouraging development for\nMangoceuticals,” said Jacob D. Cohen, Chief Executive Officer. “These\ntransactions demonstrate our focus on pursuing financing structures suited to\ndifferent parts of our business. We intend to build on this momentum as we\nadvance commercialization initiatives and evaluate opportunities to create\nlong-term shareholder value.”\n\nTransaction Details\n\nThe approximately $500,000 registered direct offering closed on October 9,\n2026. The offering was priced at $0.75 per unit, with each unit consisting of\none share of common stock and one warrant. The unit purchase price represents\nan approximately 74% premium to the Company’s referenced recent closing\nshare price of $0.43. The transaction’s economic terms are described in the\nCompany's Current Report on Form 8-K filed with the SEC on October 9, 2026\n(the “Form 8-K”). Investors should review the Form 8-K and the offering\ndocuments filed as exhibits to the Form 8-K to understand the potential\ndilution that could result from exercises of the warrants.\n\nThe offering was made pursuant to an effective shelf registration statement on\nForm S-3 (No. 333-288039) previously filed with the U.S. Securities and\nExchange Commission (SEC) and declared effective by the SEC on June 24, 2025.\nA final prospectus supplement and accompanying prospectus describing the terms\nof the proposed offering were filed with the SEC and are available on the\nSEC’s website located at www.sec.gov. Electronic copies of the final\nprospectus supplement and the accompanying prospectus may be obtained by\ncontacting the Company at 17130 Dallas Parkway, Suite 240, Dallas, TX 75248,\nby email at investors@mangorx.com, or by telephone at +1 (214) 242-9619.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy nor shall there be any sale of these securities in any\nstate or jurisdiction in which such offer, solicitation or sale would be\nunlawful prior to registration or qualification under the securities laws of\nany such state or jurisdiction.\n\nAbout Mangoceuticals, Inc.\n\nMangoRx is focused on developing a variety of men’s health and wellness\nproducts and services via a secure telemedicine platform. The Company\ncurrently offers pharmaceutical-based products specifically related to the\ntreatments of erectile dysfunction, hair growth, hormone replacement\ntherapies, and weight management. Interested consumers can use MangoRx’s\ntelemedicine platform for a smooth experience. Prescription requests will be\nreviewed by a licensed medical provider and, if approved, fulfilled and\ndiscreetly shipped through MangoRx’s partner compounding pharmacy and right\nto the patient’s doorstep. To learn more about MangoRx’s mission and other\nproducts, please visit www.MangoRx.com.\n\nCautionary Note Regarding Forward-Looking Statements\n\nCertain statements made in this press release contain forward-looking\ninformation within the meaning of applicable securities laws, including within\nthe meaning of the Private Securities Litigation Reform Act of 1995\n(“forward-looking statements”). These forward-looking statements represent\nthe Company’s current expectations or beliefs concerning future events and\ncan generally be identified using statements that include words such as\n“estimate,” “expects,” “project,” “believe,” “anticipate,”\n“intend,” “plan,” “foresee,” “forecast,” “likely,”\n“will,” “target,” “up to” or similar words or phrases. These\nforward-looking statements include, but are not limited to, the timing and\nreceipt of the second tranche of subscription funds discussed above, the use\nof the proceeds of the investments and the outcome thereof; and the\ncommercialization and monetization of MangoRx IP’s intellectual property.\nAlthough we believe that our plans, intentions and expectations reflected in\nor suggested by the forward-looking statements we make in this release are\nreasonable, we provide no assurance that these plans, intentions or\nexpectations will be achieved. Consequently, you should not consider any such\nlist to be a complete set of all potential risks and uncertainties.\n\nMore information on potential factors that could affect the Company’s\nfinancial results is included from time to time in the “Cautionary Note\nRegarding Forward-Looking Statements,” “Risk Factors” and\n“Management’s Discussion and Analysis of Financial Condition and Results\nof Operations” sections of the Company’s filings with the SEC, including\nthe Company’s Annual Report on Form 10-K for the year ended December 31,\n2025 and our Quarterly Report on Form 10-Q for the quarter ended June 30,\n2026, and subsequent reports. These filings are available at www.sec.gov and\nat our website at https://www.mangoceuticals.com/sec-filings. All subsequent\nwritten and oral forward-looking statements attributable to the Company or any\nperson acting on behalf of the Company are expressly qualified in their\nentirety by the cautionary statements referenced above. Other unknown or\nunpredictable factors also could have material adverse effects on the\nCompany’s future results. The forward-looking statements included in this\npress release are made only as of the date hereof. The Company cannot\nguarantee future results, levels of activity, performance or achievements.\nAccordingly, you should not place undue reliance on these forward-looking\nstatements. Finally, the Company undertakes no obligation to update these\nstatements after the date of this release, except as required by law, and\ntakes no obligation to update or correct information prepared by third parties\nthat are not paid for by the Company. If we update one or more forward-looking\nstatements, no inference should be drawn that we will make additional updates\nwith respect to those or other forward-looking statements.\n\nFOR INVESTOR RELATIONS Email: investors@mangorx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/424c2f93-0321-4df2-98b6-6a7970d20bd4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-09T20:01:00.153003574Z","server_sent_at_ms":1791576060153},"received_at":"2026-10-09T20:01:00.204Z","source_url":null},"analysis":{"id":"154097","press_release_id":"165711","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["warrants attached to each unit introduce potential future dilution; terms not detailed in the release","remaining $750,000 subsidiary tranche is subject to agreement terms and not yet funded","micro-cap company with sub-$1 stock still reliant on small sequential raises"],"eventType":"offering","narrative":"Mangoceuticals closed an approximately $500,000 registered direct offering priced at $0.75 per unit, roughly a 74% premium to its referenced recent close of $0.43. Each unit consists of one share of common stock plus one warrant.\n\nThe financing follows $2.5 million in strategic investment commitments at subsidiary MangoRx IP Holdings, of which $1.75 million has been received, with the remaining $750,000 due by November 28, 2026. The subsidiary-level funding did not require issuance of parent common stock.\n\nManagement framed the above-market pricing as a vote of confidence, though the company directs investors to its October 9 Form 8-K for details on potential dilution from warrant exercises.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Micro-cap telehealth firm MangoRx closes an above-market registered direct at a 74% premium — unusual structure worth a second look at the warrant terms in the 8-K."},"keyFigures":{"dealValueUsd":500000,"offeringPrice":0.75,"customDimensions":{"recent_close":"$0.43","premium_to_close":"approximately 74%","membership_interest_sold":"25%","subsidiary_capital_received":"$1.75 million","subsidiary_capital_remaining":"$750,000 due by November 28, 2026","subsidiary_investment_commitments":"$2.5 million"}},"quotedText":"We believe the ability to attract a direct investment at a substantial premium to our recent trading price, shortly after securing strategic capital commitments for MangoRx IP, is an encouraging development for Mangoceuticals","namedEntities":{"people":[{"name":"Jacob D. Cohen","role":"CEO"}],"products":["MangoRx","PeachesRx"],"companies":[{"name":"Mangoceuticals, Inc.","ticker":"MGRX","relationship":"filer"},{"name":"MangoRx IP Holdings, LLC","ticker":"MGRX","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"$2.5 million","context":"strategic investment commitments to MangoRx IP Holdings"},{"amount":"$1.75 million","context":"committed capital received to date by MangoRx IP"},{"amount":"$750,000","context":"remaining committed capital due by November 28, 2026"},{"amount":"$500,000","context":"approximate size of registered direct offering"},{"amount":"$0.75","context":"per-unit offering price"},{"amount":"$0.43","context":"referenced recent closing share price"}]},"materialImpact":{"score":2,"reasoning":"A small (~$500K) registered direct offering closed, but unusually priced at a 74% premium to the recent close, a favorable signal; significance is limited by micro-cap scale and undisclosed warrant dilution terms."},"tickerRelevance":{"others":[],"primary":"MGRX"},"globalImportance":10,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"small financing, above-market pricing","unusualStructure":"premium-priced offering with warrants","retailFavoriteBoost":false}},"event_type":"offering","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Mangoceuticals closed an approximately $500,000 registered direct offering priced at $0.75 per unit, roughly a 74% premium to its referenced recent close of $0.43. Each unit consists of one share of common stock plus one warrant.\n\nThe financing follows $2.5 million in strategic investment commitments at subsidiary MangoRx IP Holdings, of which $1.75 million has been received, with the remaining $750,000 due by November 28, 2026. The subsidiary-level funding did not require issuance of parent common stock.\n\nManagement framed the above-market pricing as a vote of confidence, though the company directs investors to its October 9 Form 8-K for details on potential dilution from warrant exercises.","key_figures":{"dealValueUsd":500000,"offeringPrice":0.75,"customDimensions":{"recent_close":"$0.43","premium_to_close":"approximately 74%","membership_interest_sold":"25%","subsidiary_capital_received":"$1.75 million","subsidiary_capital_remaining":"$750,000 due by November 28, 2026","subsidiary_investment_commitments":"$2.5 million"}},"named_entities":{"people":[{"name":"Jacob D. Cohen","role":"CEO"}],"products":["MangoRx","PeachesRx"],"companies":[{"name":"Mangoceuticals, Inc.","ticker":"MGRX","relationship":"filer"},{"name":"MangoRx IP Holdings, LLC","ticker":"MGRX","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"$2.5 million","context":"strategic investment commitments to MangoRx IP Holdings"},{"amount":"$1.75 million","context":"committed capital received to date by MangoRx IP"},{"amount":"$750,000","context":"remaining committed capital due by November 28, 2026"},{"amount":"$500,000","context":"approximate size of registered direct offering"},{"amount":"$0.75","context":"per-unit offering price"},{"amount":"$0.43","context":"referenced recent closing share price"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-09T20:01:10.123Z","global_importance":10,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap","eventGravity":"small financing, above-market pricing","unusualStructure":"premium-priced offering with warrants","retailFavoriteBoost":false}},"durationMs":9898,"modelName":"glm-5.3-flashx"}}